Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Royalty Pharma Cash Provided by (Used in) Operating Activity, Including Discontinued Operation decreased by 13.2% to $718.23M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.5%, from $596.08M to $718.23M. Over 4 years (FY 2021 to FY 2025), Cash Provided by (Used in) Operating Activity, Including Discontinued Operation shows an upward trend with a 5.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
A comprehensive measure of the company's total cash generation efficiency.
Detailed definition
The consolidated net cash flow from operating activities, including both continuing and discontinued operations. It prov...
Peer comparison
Standard consolidated cash flow metric used by all global enterprises.
other_net_cash_provided_by_used_in_operating_activitiesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $531.72M | $469.76M | $489.96M | $460.27M | $574.95M | $538.83M | $569.93M | $1.03B | $607.82M | $573.52M | $772.63M | $664.64M | $658.21M | $703.61M | $742.53M | $596.08M | $363.98M | $702.62M | $827.15M | $718.23M |
| QoQ Change | — | -11.7% | +4.3% | -6.1% | +24.9% | -6.3% | +5.8% | +81.4% | -41.2% | -5.6% | +34.7% | -14.0% | -1.0% | +6.9% | +5.5% | -19.7% | -38.9% | +93.0% | +17.7% | -13.2% |
| YoY Change | — | — | — | — | +8.1% | +14.7% | +16.3% | +124.6% | +5.7% | +6.4% | +35.6% | -35.7% | +8.3% | +22.7% | -3.9% | -10.3% | -44.7% | -0.1% | +11.4% | +20.5% |
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's cash provided by (used in) operating activity, including discontinued operation?
- Royalty Pharma (RPRX) reported cash provided by (used in) operating activity, including discontinued operation of $718.23M in Q1 2026.
- How has Royalty Pharma's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
- Royalty Pharma's cash provided by (used in) operating activity, including discontinued operation increased by 20.5% year-over-year, from $596.08M to $718.23M.
- What is the long-term trend for Royalty Pharma's cash provided by (used in) operating activity, including discontinued operation?
- Over 4 years (2021 to 2025), Royalty Pharma's cash provided by (used in) operating activity, including discontinued operation has grown at a 5.4% compound annual growth rate (CAGR), from $2.02B to $2.49B.
- What does cash provided by (used in) operating activity, including discontinued operation mean?
- Total net cash flow from all operating activities, including discontinued units.